MET and head and neck cancer: To validate these pre-clinical findings we analyzed in silico publicly available data sets of HNSCC patients from The Cancer Genome Atlas (TCGA) (n = 473) [7] and the HIPO-HNC study (Heidelberg Center for Personalized Oncology-head and neck cancer) (n = 77) [42,43] and correlated the MET gene expression with clinicopathological characteristics that influence radiotherapy response.